Richard Ofori-Asenso1,2,3, Jenni Ilomäki4,5, Mark Tacey1, Si Si1, Andrea J Curtis3, Ella Zomer1, J Simon Bell4,5,6, Sophia Zoungas3, Danny Liew1. 1. Centre of Cardiovascular Research and Education in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 2. Epidemiological Modelling Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 3. Division of Metabolism, Ageing and Genomics, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 4. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia. 5. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 6. School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Abstract
AIMS: The aim of this study was to examine the level of and predictors of statin nonadherence and discontinuation among older adults. METHODS: Among 22 340 Australians aged ≥65 years who initiated statin therapy from January 2014 to December 2015, we estimated the first-year nonadherence (proportion of days covered [PDC] <0.80) and discontinuation (≥90 days without statin coverage) rates. Predictors of nonadherence and discontinuation were examined via multivariable logistic regression. Analyses were performed separately for general beneficiaries (with a higher co-payment; n = 4841) and concessional beneficiaries (with a lower co-payment; n = 17 499). RESULTS: During the one-year follow-up, 55.1% were nonadherent (concessional 52.6%; general beneficiaries 64.2%) and 44.7% discontinued statins (concessional 43.1%; general beneficiaries 50.4%). Among concessional beneficiaries, those aged 75-84 years and ≥85 years were more likely to discontinue than people aged 65-74 years (odds ratio 1.11, 95% confidence interval 1.04-1.19 and 1.38, 1.23-1.54, respectively). Diabetes was associated with an increased likelihood of nonadherence and discontinuation, while hypertension, angina and congestive heart failure were associated with a lower likelihood of nonadherence and discontinuation. Anxiety was associated with an increased likelihood of discontinuation, but polypharmacy (concurrent use of five or more drugs) was associated with a lower likelihood of nonadherence and discontinuation. Statin initiation by a general medical practitioner was associated with both increased likelihood of nonadherence and discontinuation. Similar predictors of nonadherence and discontinuation were identified for the general beneficiaries. CONCLUSIONS: Among older adults prescribed statins, first-year nonadherence and discontinuation are high. Specific population subgroups such as people aged ≥85 years, those with diabetes or anxiety may require additional attention to improve statin adherence.
AIMS: The aim of this study was to examine the level of and predictors of statin nonadherence and discontinuation among older adults. METHODS: Among 22 340 Australians aged ≥65 years who initiated statin therapy from January 2014 to December 2015, we estimated the first-year nonadherence (proportion of days covered [PDC] <0.80) and discontinuation (≥90 days without statin coverage) rates. Predictors of nonadherence and discontinuation were examined via multivariable logistic regression. Analyses were performed separately for general beneficiaries (with a higher co-payment; n = 4841) and concessional beneficiaries (with a lower co-payment; n = 17 499). RESULTS: During the one-year follow-up, 55.1% were nonadherent (concessional 52.6%; general beneficiaries 64.2%) and 44.7% discontinued statins (concessional 43.1%; general beneficiaries 50.4%). Among concessional beneficiaries, those aged 75-84 years and ≥85 years were more likely to discontinue than people aged 65-74 years (odds ratio 1.11, 95% confidence interval 1.04-1.19 and 1.38, 1.23-1.54, respectively). Diabetes was associated with an increased likelihood of nonadherence and discontinuation, while hypertension, angina and congestive heart failure were associated with a lower likelihood of nonadherence and discontinuation. Anxiety was associated with an increased likelihood of discontinuation, but polypharmacy (concurrent use of five or more drugs) was associated with a lower likelihood of nonadherence and discontinuation. Statin initiation by a general medical practitioner was associated with both increased likelihood of nonadherence and discontinuation. Similar predictors of nonadherence and discontinuation were identified for the general beneficiaries. CONCLUSIONS: Among older adults prescribed statins, first-year nonadherence and discontinuation are high. Specific population subgroups such as people aged ≥85 years, those with diabetes or anxiety may require additional attention to improve statin adherence.
Authors: Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew Journal: Br J Clin Pharmacol Date: 2018-11-08 Impact factor: 4.335
Authors: Andrea L Schaffer; Nicholas A Buckley; Timothy A Dobbins; Emily Banks; Sallie-Anne Pearson Journal: Med J Aust Date: 2015-06-15 Impact factor: 7.738
Authors: Sohan Deshpande; Ruben G W Quek; Carol A Forbes; Shelley de Kock; Jos Kleijnen; Shravanthi R Gandra; Ross J Simpson Journal: Curr Med Res Opin Date: 2017-01-20 Impact factor: 2.580
Authors: Richard Ofori-Asenso; Avtar Jakhu; Ella Zomer; Andrea J Curtis; Maarit Jaana Korhonen; Mark Nelson; Manoj Gambhir; Andrew Tonkin; Danny Liew; Sophia Zoungas Journal: J Gerontol A Biol Sci Med Sci Date: 2018-05-09 Impact factor: 6.053
Authors: P Michael Ho; John A Spertus; Frederick A Masoudi; Kimberly J Reid; Eric D Peterson; David J Magid; Harlan M Krumholz; John S Rumsfeld Journal: Arch Intern Med Date: 2006-09-25
Authors: Richard Ofori-Asenso; Jenni Ilomäki; Mark Tacey; Si Si; Andrea J Curtis; Ella Zomer; J Simon Bell; Sophia Zoungas; Danny Liew Journal: Br J Clin Pharmacol Date: 2018-11-08 Impact factor: 4.335
Authors: Martin Wawruch; Gejza Wimmer; Jan Murin; Martina Paduchova; Tomas Tesar; Lubica Hlinkova; Peter Slavkovsky; Lubomira Fabryova; Emma Aarnio Journal: Drugs Aging Date: 2019-09 Impact factor: 3.923
Authors: Catherine A Panozzo; Lesley H Curtis; James Marshall; Lawrence Fine; Barbara L Wells; Jeffrey S Brown; Kevin Haynes; Pamala A Pawloski; Adrian F Hernandez; Sarah Malek; Beth Syat; Richard Platt Journal: PLoS One Date: 2019-12-05 Impact factor: 3.240
Authors: Amitava Banerjee; Valerio Benedetto; Philip Gichuru; Jane Burnell; Sotiris Antoniou; Richard J Schilling; William David Strain; Ronan Ryan; Caroline Watkins; Tom Marshall; Chris J Sutton Journal: Heart Date: 2019-10-10 Impact factor: 5.994
Authors: Renata Cristina Rezende Macedo do Nascimento; Tanja Mueller; Brian Godman; Sean MacBride Stewart; Simon Hurding; Francisco de Assis Acurcio; Augusto Afonso Guerra Junior; Juliana Alvares Teodoro; Alec Morton; Marion Bennie; Amanj Kurdi Journal: Br J Clin Pharmacol Date: 2020-05-30 Impact factor: 4.335
Authors: In Sun Ryou; Jooyoung Chang; Joung Sik Son; Ahryoung Ko; Seulggie Choi; Kyuwoong Kim; Sung Min Kim; Sang Min Park Journal: BMJ Open Date: 2021-04-07 Impact factor: 2.692
Authors: Oscar Kristiansen; Nils T Vethe; Morten W Fagerland; Stein Bergan; John Munkhaugen; Einar Husebye Journal: Br J Clin Pharmacol Date: 2019-11-03 Impact factor: 4.335
Authors: Carlos Lahoz; Juan Cárdenas-Valladolid; Miguel Ángel Salinero-Fort; José María Mostaza Journal: Aging Clin Exp Res Date: 2021-08-07 Impact factor: 4.481